{"pmid":32092748,"title":"COVID-19: Real-time dissemination of scientific information to fight a public health emergency of international concern.","text":["COVID-19: Real-time dissemination of scientific information to fight a public health emergency of international concern.","Rapidly sharing scientific information is an effective way to reduce public panic about COVID-19, and doing so is the key to providing real-time guidance to epidemiologists working to contain the outbreak, clinicians managing patients, and modelers helping to understand future developments and the possible effectiveness of various interventions. This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies. As an academic journal, we will continue to quickly and transparently share data with frontline healthcare workers who need to know the epidemiological and clinical features of COVID-19.","Biosci Trends","Song, Peipei","Karako, Takashi","32092748"],"abstract":["Rapidly sharing scientific information is an effective way to reduce public panic about COVID-19, and doing so is the key to providing real-time guidance to epidemiologists working to contain the outbreak, clinicians managing patients, and modelers helping to understand future developments and the possible effectiveness of various interventions. This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies. As an academic journal, we will continue to quickly and transparently share data with frontline healthcare workers who need to know the epidemiological and clinical features of COVID-19."],"journal":"Biosci Trends","authors":["Song, Peipei","Karako, Takashi"],"date":"2020-02-25T11:00:00Z","year":2020,"_id":"32092748","week":"20209|Feb 24 - Mar 01","doi":"10.5582/bst.2020.01056","keywords":["2019-nCoV","COVID-19","SARS-CoV-2","sharing data"],"source":"PubMed","locations":["Chinese","Western"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["General Info"],"weight":1,"_version_":1661359647425036288,"score":6.7365713,"similar":[{"pmid":32074550,"title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.","text":["Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.","The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China. Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China. The drug is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People's Republic of China for treatment of COVID-19 infection in larger populations in the future.","Biosci Trends","Gao, Jianjun","Tian, Zhenxue","Yang, Xu","32074550"],"abstract":["The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China. Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China. The drug is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People's Republic of China for treatment of COVID-19 infection in larger populations in the future."],"journal":"Biosci Trends","authors":["Gao, Jianjun","Tian, Zhenxue","Yang, Xu"],"date":"2020-02-20T11:00:00Z","year":2020,"_id":"32074550","week":"20208|Feb 17 - Feb 23","doi":"10.5582/bst.2020.01047","keywords":["2019-nCoV","COVID-19","SARS-CoV-2","chloroquine","pneumonia"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647342198784,"score":158.52298},{"pmid":32062645,"title":"Challenges to the system of reserve medical supplies for public health emergencies: reflections on the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in China.","text":["Challenges to the system of reserve medical supplies for public health emergencies: reflections on the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in China.","On December 31, 2019, the Wuhan Municipal Health Commission announced an outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), China is now at a critical period in the control of the epidemic. The Chinese Government has been taking a series of rapid, comprehensive, and effective prevention and control measures. As the pandemic has developed, a fact has become apparent: there is a serious dearth of emergency medical supplies, and especially an extreme shortage of personal protective equipment such as masks and medical protective clothing. This is one of the major factors affecting the progress of epidemic prevention and control. Although China has made great efforts to strengthen the ability to quickly respond to public health emergencies since the SARS outbreak in 2003 and it has clarified requirements for emergency supplies through legislation, the emergency reserve supplies program has not been effectively implemented, and there are also deficiencies in the types, quantity, and availability of emergency medical supplies. A sound system of emergency reserve supplies is crucial to the management of public health emergencies. Based on international experiences with pandemic control, the world should emphasize improving the system of emergency reserve medical supplies in the process of establishing and improving public health emergency response systems, and it should promote the establishment of international cooperative programs to jointly deal with public health emergencies of international concern in the future.","Biosci Trends","Wang, Xu","Zhang, Xiaoxi","He, Jiangjiang","32062645"],"abstract":["On December 31, 2019, the Wuhan Municipal Health Commission announced an outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), China is now at a critical period in the control of the epidemic. The Chinese Government has been taking a series of rapid, comprehensive, and effective prevention and control measures. As the pandemic has developed, a fact has become apparent: there is a serious dearth of emergency medical supplies, and especially an extreme shortage of personal protective equipment such as masks and medical protective clothing. This is one of the major factors affecting the progress of epidemic prevention and control. Although China has made great efforts to strengthen the ability to quickly respond to public health emergencies since the SARS outbreak in 2003 and it has clarified requirements for emergency supplies through legislation, the emergency reserve supplies program has not been effectively implemented, and there are also deficiencies in the types, quantity, and availability of emergency medical supplies. A sound system of emergency reserve supplies is crucial to the management of public health emergencies. Based on international experiences with pandemic control, the world should emphasize improving the system of emergency reserve medical supplies in the process of establishing and improving public health emergency response systems, and it should promote the establishment of international cooperative programs to jointly deal with public health emergencies of international concern in the future."],"journal":"Biosci Trends","authors":["Wang, Xu","Zhang, Xiaoxi","He, Jiangjiang"],"date":"2020-02-17T11:00:00Z","year":2020,"_id":"32062645","week":"20208|Feb 17 - Feb 23","doi":"10.5582/bst.2020.01043","keywords":["COVID-19","SARS-CoV-2","medical supplies","public health emergency"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["General Info"],"weight":1,"_version_":1661359647308644352,"score":143.85037},{"pmid":32133578,"title":"Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19).","text":["Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19).","In late December 2019, a cluster of cases with 2019 Novel Coronavirus pneumonia (SARS-CoV-2) in Wuhan, China, aroused worldwide concern. Previous studies have reported epidemiological and clinical characteristics of coronavirus disease 2019 (COVID-19). The purpose of this brief review is to summarize those published studies as of late February 2020 on the clinical features, symptoms, complications, and treatments of COVID-19 and help provide guidance for frontline medical staff in the clinical management of this outbreak.","J Gen Intern Med","Jiang, Fang","Deng, Liehua","Zhang, Liangqing","Cai, Yin","Cheung, Chi Wai","Xia, Zhengyuan","32133578"],"abstract":["In late December 2019, a cluster of cases with 2019 Novel Coronavirus pneumonia (SARS-CoV-2) in Wuhan, China, aroused worldwide concern. Previous studies have reported epidemiological and clinical characteristics of coronavirus disease 2019 (COVID-19). The purpose of this brief review is to summarize those published studies as of late February 2020 on the clinical features, symptoms, complications, and treatments of COVID-19 and help provide guidance for frontline medical staff in the clinical management of this outbreak."],"journal":"J Gen Intern Med","authors":["Jiang, Fang","Deng, Liehua","Zhang, Liangqing","Cai, Yin","Cheung, Chi Wai","Xia, Zhengyuan"],"date":"2020-03-06T11:00:00Z","year":2020,"_id":"32133578","week":"202010|Mar 02 - Mar 08","doi":"10.1007/s11606-020-05762-w","keywords":["COVID-19","SARS-CoV-2","Wuhan","coronavirus","pneumonia","review"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1661359647688228864,"score":141.66832},{"pmid":32029004,"pmcid":"PMC7003341","title":"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version).","text":["A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version).","In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province; and then named \"2019 novel coronavirus (2019-nCoV)\" by the World Health Organization (WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world's attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development; we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control (including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV.","Mil Med Res","Jin, Ying-Hui","Cai, Lin","Cheng, Zhen-Shun","Cheng, Hong","Deng, Tong","Fan, Yi-Pin","Fang, Cheng","Huang, Di","Huang, Lu-Qi","Huang, Qiao","Han, Yong","Hu, Bo","Hu, Fen","Li, Bing-Hui","Li, Yi-Rong","Liang, Ke","Lin, Li-Kai","Luo, Li-Sha","Ma, Jing","Ma, Lin-Lu","Peng, Zhi-Yong","Pan, Yun-Bao","Pan, Zhen-Yu","Ren, Xue-Qun","Sun, Hui-Min","Wang, Ying","Wang, Yun-Yun","Weng, Hong","Wei, Chao-Jie","Wu, Dong-Fang","Xia, Jian","Xiong, Yong","Xu, Hai-Bo","Yao, Xiao-Mei","Yuan, Yu-Feng","Ye, Tai-Sheng","Zhang, Xiao-Chun","Zhang, Ying-Wen","Zhang, Yin-Gao","Zhang, Hua-Min","Zhao, Yan","Zhao, Ming-Juan","Zi, Hao","Zeng, Xian-Tao","Wang, Yong-Yan","Wang, Xing-Huan","32029004"],"abstract":["In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province; and then named \"2019 novel coronavirus (2019-nCoV)\" by the World Health Organization (WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world's attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development; we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control (including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV."],"journal":"Mil Med Res","authors":["Jin, Ying-Hui","Cai, Lin","Cheng, Zhen-Shun","Cheng, Hong","Deng, Tong","Fan, Yi-Pin","Fang, Cheng","Huang, Di","Huang, Lu-Qi","Huang, Qiao","Han, Yong","Hu, Bo","Hu, Fen","Li, Bing-Hui","Li, Yi-Rong","Liang, Ke","Lin, Li-Kai","Luo, Li-Sha","Ma, Jing","Ma, Lin-Lu","Peng, Zhi-Yong","Pan, Yun-Bao","Pan, Zhen-Yu","Ren, Xue-Qun","Sun, Hui-Min","Wang, Ying","Wang, Yun-Yun","Weng, Hong","Wei, Chao-Jie","Wu, Dong-Fang","Xia, Jian","Xiong, Yong","Xu, Hai-Bo","Yao, Xiao-Mei","Yuan, Yu-Feng","Ye, Tai-Sheng","Zhang, Xiao-Chun","Zhang, Ying-Wen","Zhang, Yin-Gao","Zhang, Hua-Min","Zhao, Yan","Zhao, Ming-Juan","Zi, Hao","Zeng, Xian-Tao","Wang, Yong-Yan","Wang, Xing-Huan"],"date":"2020-02-08T11:00:00Z","year":2020,"_id":"32029004","week":"20206|Feb 03 - Feb 09","doi":"10.1186/s40779-020-0233-6","keywords":["2019 novel coronavirus","2019-nCoV","Clinical practice guideline","Evidence-based medicine","Infectious diseases","Pneumonia","Rapid advice guideline","Respiratory disease"],"source":"PubMed","locations":["Chinese","Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647052791808,"score":137.53958},{"pmid":32022370,"title":"Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.","text":["Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV.","With the current trajectory of the 2019-nCoV outbreak unknown, public health and medicinal measures will both be needed to contain spreading of the virus and to optimize patient outcomes. Although little is known about the virus, an examination of the genome sequence shows strong homology with its better-studied cousin, SARS-CoV. The spike protein used for host cell infection shows key nonsynonymous mutations that might hamper the efficacy of previously developed therapeutics but remains a viable target for the development of biologics and macrocyclic peptides. Other key drug targets, including RNA-dependent RNA polymerase and coronavirus main proteinase (3CLpro), share a strikingly high (>95 %) homology to SARS-CoV. Herein, we suggest four potential drug candidates (an ACE2-based peptide, remdesivir, 3CLpro-1 and a novel vinylsulfone protease inhibitor) that could be used to treat patients suffering with the 2019-nCoV. We also summarize previous efforts into drugging these targets and hope to help in the development of broad-spectrum anti-coronaviral agents for future epidemics.","Chembiochem","Morse, Jared S","Lalonde, Tyler","Xu, Shiqing","Liu, Wenshe Ray","32022370"],"abstract":["With the current trajectory of the 2019-nCoV outbreak unknown, public health and medicinal measures will both be needed to contain spreading of the virus and to optimize patient outcomes. Although little is known about the virus, an examination of the genome sequence shows strong homology with its better-studied cousin, SARS-CoV. The spike protein used for host cell infection shows key nonsynonymous mutations that might hamper the efficacy of previously developed therapeutics but remains a viable target for the development of biologics and macrocyclic peptides. Other key drug targets, including RNA-dependent RNA polymerase and coronavirus main proteinase (3CLpro), share a strikingly high (>95 %) homology to SARS-CoV. Herein, we suggest four potential drug candidates (an ACE2-based peptide, remdesivir, 3CLpro-1 and a novel vinylsulfone protease inhibitor) that could be used to treat patients suffering with the 2019-nCoV. We also summarize previous efforts into drugging these targets and hope to help in the development of broad-spectrum anti-coronaviral agents for future epidemics."],"journal":"Chembiochem","authors":["Morse, Jared S","Lalonde, Tyler","Xu, Shiqing","Liu, Wenshe Ray"],"date":"2020-02-06T11:00:00Z","year":2020,"_id":"32022370","week":"20206|Feb 03 - Feb 09","doi":"10.1002/cbic.202000047","keywords":["2019-nCoV","3CLpro","RdRp","SARS","antiviral agents","coronavirus","spike proteins"],"source":"PubMed","locations":["ACE2-based"],"topics":["General Info"],"weight":1,"_version_":1661359647150309377,"score":136.8516}]}